Management of Unstable Arrhythmias in Cardiogenic Shock

Heart Failure

Opinion statement

Atrial and ventricular arrhythmias commonly arise in the setting of cardiogenic shock and often result in hemodynamic deterioration. Causative factors include myocardial ischemia, volume overload, and metabolic disturbances. Correcting these factors plays an important role in managing arrhythmias in this setting. Ventricular arrhythmias are more ominous compared to atrial arrhythmias but both require prompt intervention with electrical shock and anti-arrhythmic drug suppression. Coronary reperfusion is key to improving survival, including reducing the risk of sudden cardiac arrest, in acute myocardial infarction. Case series have also demonstrated the value of intra-aortic balloon pump counter-pulsation in suppressing ventricular arrhythmias in cardiogenic shock. The mechanism of arrhythmia suppression may be due to improved coronary perfusion and afterload reduction. Percutaneous ventricular assist device placement may be effective in this setting; however, data addressing this specific endpoint are lacking. Anti-arrhythmic drug options for ventricular and atrial arrhythmia suppression, in the setting of cardiogenic shock, are relatively limited. Common class I agents are excluded due to the inherent abnormal cardiac structure and function in the setting of cardiogenic shock. Class III drug options include dofetilide and amiodarone. The other Class III agents, sotalol and dronedarone, are excluded due to associated mortality observed in the SWORD and ANDROMEDA trials, respectively. Dofetilide is renally excreted and causes QT interval prolongation. Care should be taken to avoid excessive drug accumulation due to poor kidney perfusion and function. Dofetilide is approved for use for atrial arrhythmias and has not been studied for ventricular arrhythmia suppression. The DIAMOND-CHF trial established its safety in the setting of heart failure. Amiodarone is very effective in suppressing both atrial and ventricular arrhythmias. It is often the drug of choice in heart failure. Its off-label use for atrial arrhythmias is very common. Care should be taken with intravenous amiodarone to avoid hypotension.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.•
    Goldberg RJ, Spencer FA, Gore JM, et al. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation. 2009;119(9):1211–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Babaev A, Frederick PD, Pasta DJ, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2005;294(4):448–54.PubMedCrossRefGoogle Scholar
  3. 3.
    • Reynolds HR, Hochman JS, et al. Cardiogenic shock: current concepts and improving outcomes. Circulation. 2008;117(5):686–97.PubMedCrossRefGoogle Scholar
  4. 4.
    Zannad F, Mebazaa A, Juillière Y, et al. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: the EFICA study. Eur J Heart Fail. 2006;8(7):697–705. Epub 2006 Mar 3.PubMedCrossRefGoogle Scholar
  5. 5.
    Jeger RV, Assmann SF, Yehudai L, et al. Causes of death and re-hospitalization in cardiogenic shock. Acute Card Care. 2007;9(1):25–33.PubMedCrossRefGoogle Scholar
  6. 6.
    Dzavik V, Sleeper LA, Cocke TP, et al. Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry. Eur Heart J. 2003;24(9):828–37.PubMedCrossRefGoogle Scholar
  7. 7.
    Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. JAMA. 2001;285(2):190–2.PubMedCrossRefGoogle Scholar
  8. 8.
    Carnendran L, Abboud R, Sleeper LA, et al. Trends in cardiogenic shock: report from the SHOCK Study. The SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? Eur Heart J. 2001;22(6):472–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Entwistle 3rd JW, Bolno PB, Holmes E, et al. Improved survival with ventricular assist device support in cardiogenic shock after myocardial infarction. Heart Surg Forum. 2003;6(5):316–9.PubMedGoogle Scholar
  10. 10.
    Benza RL, Tallaj JA, Felker GM, et al. The impact of arrhythmias in acute heart failure. J Card Fail. 2004;10(4):279–84.PubMedCrossRefGoogle Scholar
  11. 11.
    DiMarco JP. Atrial fibrillation and acute decompensated heart failure. Circ Heat Fail. 2009;2(1):72–3.CrossRefGoogle Scholar
  12. 12.
    Knight BP, Michaud GF, Strickberger SA, et al. Electrocardiographic differentiation of atrial flutter from atrial fibrillation by physicians. J Electrocardiol. 1999;32:315–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Fauci AS, Braunwald E, Kasper AS, Hauser SL. The tachyarrhythmias. Harrison’s Principles of Internal Medicine 17th edition. Chapter 226. p. 1437.Google Scholar
  14. 14.
    Jeger RV, Lowe AM, Buller CE, et al. Hemodynamic parameters are prognostically important in cardiogenic shock but similar following early revascularization or initial medical stabilization: a report from the SHOCK Trial. Chest. 2007;132(6):1794–803. Epub 2007Oct20.PubMedCrossRefGoogle Scholar
  15. 15.
    Torp-Pedersen C, Møller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999;341(12):857–65.PubMedCrossRefGoogle Scholar
  16. 16.
    ACC/AHA/ESC ACC/AHA/ESC 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. J Am Coll Cardiol. 2006;48:247–346, doi:10.1016/j.jacc.2006.07.010 (Published online 25 August 2006).
  17. 17.••
    Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death-executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death). J Am Coll Cardiol. 2006;48:1064.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Division of CardiologyUniversity of Utah School of MedicineSalt Lake CityUSA

Personalised recommendations